NeuroSense Therapeutics Ltd. (NRSN)

NASDAQ: NRSN · IEX Real-Time Price · USD

0.732

-0.029 (-3.76%)

At close: Jul 19, 2024, 4:00 PM

0.730

-0.002 (-0.22%)

Pre-market: Jul 20, 2024, 9:29 AM EDT

NeuroSense Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	4.78	4.78	4.97	1.59	0.39	0.34
Research & Development	7.27	7.27	5.59	1.39	2.5	0.9
Operating Expenses	12.05	12.05	10.55	2.99	2.89	1.24
Operating Income	-12.05	-12.05	-10.55	-2.99	-2.89	-1.24
Interest Expense / Income	0	0	0	0	0	0.01
Other Expense / Income	-1.94	-1.94	-0.06	0.24	-0.06	-0.02
Pretax Income	-10.11	-10.11	-10.49	-3.22	-2.83	-1.22
Net Income	-10.11	-10.11	-10.49	-3.22	-2.83	-1.22
Shares Outstanding (Basic)	14	14	12	6	6	5
Shares Outstanding (Diluted)	14	14	12	6	6	5
Shares Change	18.56%	18.56%	84.27%	13.12%	19.10%	-
EPS (Basic)	-0.74	-0.74	-0.91	-0.52	-0.51	-0.26
EPS (Diluted)	-0.74	-0.74	-0.91	-0.52	-0.51	-0.26
Free Cash Flow	-8.38	-8.38	-7.69	-1.56	-0.7	-0.59
Free Cash Flow Per Share	-0.61	-0.61	-0.67	-0.25	-0.13	-0.13
EBITDA	-10.09	-10.09	-10.48	-3.22	-2.82	-1.22
Depreciation & Amortization	0.02	0.02	0.01	0	0	0
EBIT	-10.11	-10.11	-10.49	-3.22	-2.83	-1.22

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).